Sotera Health is a high-quality healthcare sterilization business with 123% free cash flow conversion, a Piotroski F-Score of 8/9, and three consecutive earnings beats, but single-supplier dependency on one ethylene oxide source and high leverage at 3.6x debt-to-equity constrain near-term entry.
Thesis pillars
- Eo Single Supplier Concentration↑Improving
- High Quality Cash Conversion Business↓Deteriorating
- Strong Earnings Beat Streak↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Sotera Health Company (SHC) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. At $18.89, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 4.6%; Concentration risk — Supplier: EO single supplier.
Sotera Health provides outsourced sterilization (Sterigenics, Nordion) and lab testing (Nelson Labs) to medical device and pharmaceutical companies across 62 global facilities in 13 countries. Services are mandatory for regulatory compliance; customers in 2025 included over 40... Read more
Sell if holding. At $18.89, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 4.6%; Concentration risk — Supplier: EO single supplier. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Sotera Health Company
About Sotera Health Company
Sotera Health operates 62 sterilization and lab testing facilities across 13 countries, serving over 2,000 Sterigenics customers and approximately 3,000 Nelson Labs customers. More than 90% of Sterigenics revenues and approximately 90% of Nordion revenues in 2025 were from multi-year contracts, with Sterigenics achieving 100% renewal rates with its top 10 customers for more than five consecutive years. No single customer accounted for more than 10% of total revenues across either Sterigenics or Nelson Labs.
Sotera Health earns per-service fees through three business units. Sterigenics provides gamma irradiation (23 facilities), EO processing (17 facilities), and E-beam irradiation (8 facilities) services to medical device, pharmaceutical, food, and advanced applications customers. Nordion sells Co-60 radioactive isotope and gamma irradiation systems; Co-60 is sourced from contracts with three nuclear reactor operators covering 13 reactors at five Canadian and Russian generating stations, extending to dates between 2026 and 2064. Russian reactors contribute approximately 20% of long-term Co-60 supply and may reach roughly 50% in certain years due to variability at other reactor sites. EO supply in the United States comes from a single supplier with redundant production facilities. Applied Sterilization Technologies, a segment of STERIS plc, is the main global competitor to Sterigenics. Nelson Labs provides over 900 microbiological and analytical chemistry test types.
Show full overview
Sotera Health faces an EO litigation overhang that could weigh on financial results. The company is currently defending lawsuits in California, Georgia, Illinois, and New Mexico alleging personal injury and property devaluation related to EO emissions from current and former facilities. Environmental liability insurance explicitly excludes EO claims, meaning settlements or adverse judgments would be largely uninsured. Compounding this, the single ocean carrier licensed to transport Co-60 from Russia to North America holds logistics licenses subject to renewal in 2026 and 2027 under the current sanctions framework — if those licenses cannot be renewed, Co-60 supply from Russian reactors could be disrupted.
See also: Healthcare · Diagnostics & Research
From Sotera Health Company's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-16Recent Developments — Sotera Health Company
Latest news
- NEWS Sotera Health (SHC) Slips 1.3% as Stock Tests Key Support Levels - Unusual Put Volume - dars.gov.et — dars.gov.et negative
- NEWS Sotera Health (SHC) Could Be 12% Undervalued Following Warburg Pincus Exit - simplywall.st — simplywall.st positive
- NEWS Sotera Health Is Maintained at Overweight by Barclays - Moomoo — Moomoo positive
- NEWS Why Sotera Health Stock Is Dropping Despite Upgrade - TipRanks — TipRanks negative
- NEWS Sotera Health price target raised to $19 from $18 at Barclays - TipRanks — TipRanks positive
Generated 2026-08-16T18:22:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierEO single supplier10-K Item 1A: 'in the United States there is a single supplier for EO for our sterilization business'
- MEDIUMSupplierRussian nuclear reactors10-K Item 1A: 'We estimate approximately 20% of our long-term supply of Co-60 will be generated by Russian nuclear reactors... may increase to as much as approximately 50%'
Material Events(8-K, last 90d)
- 2026-05-13Item 1.02MEDIUMStockholders Agreement (dated November 19, 2020) among Sotera Health and Sponsor-affiliated stockholders terminated May 13, 2026 per its terms, following secondary offering of 31,838,253 shares at $15.168/share by Selling Stockholders via Goldman Sachs.SEC filing →
- 2026-05-05Item 5.02MEDIUMSotera Health announced leadership transition effective May 1, 2026 per executive succession plans; specific departing and incoming officer details not fully available (8-K body truncated in source).SEC filing →
- 2026-03-16Item 5.02LOWConstantine Mihas resigned as Class I director effective March 16, 2026, due to reduction in director designation rights for Sponsors. No disagreement cited. Kenneth Krause appointed as replacement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $18.89, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 4.6%; Concentration risk — Supplier: EO single supplier. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $17.81. Score 5.9/10, moderate confidence.
Take-profit target: $19.77 (+4.6% upside). Prior stop was $17.81. Stop-loss: $17.81.
Concentration risk — Supplier: EO single supplier; Thin upside margin: 4.6%; Near 52-week high (4.8% away).
Sotera Health Company trades at a P/E of 33.1 (forward 17.6). TrendMatrix value score: 6.5/10. Verdict: Sell.
15 analysts cover SHC with a consensus score of 4.1/5. Average price target: $23.
What does Sotera Health Company do?Sotera Health provides outsourced sterilization (Sterigenics, Nordion) and lab testing (Nelson Labs) to medical device...
Sotera Health provides outsourced sterilization (Sterigenics, Nordion) and lab testing (Nelson Labs) to medical device and pharmaceutical companies across 62 global facilities in 13 countries. Services are mandatory for regulatory compliance; customers in 2025 included over 40 of the top 50 medical device companies. Multi-year contracts covered 90%+ of Sterigenics and Nordion revenues.